Diligence memo · auto-generated · as of July 2, 2026
Attenua, Inc.
Attenua, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Attenua, Inc. operates in Pharmaceuticals, based in Menlo Park.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Attenua, Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2018-04-17.
Most recent recorded round closed around 2018-04-17.
Valuation (modeled)modeled
Provath models Attenua, Inc. at approximately $517M (range $32M–$2.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.76× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era. Within the normal band (76% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 8.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 62% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: LP Investors, LLC, GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co.
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.